BioXcel Therapeutics, Inc.

NasdaqCM:BTAI 주식 리포트

시가총액: US$26.6m

BioXcel Therapeutics 대차대조표 건전성

재무 건전성 기준 점검 0/6

BioXcel Therapeutics 의 총 주주 지분은 $-105.5M 이고 총 부채는 $100.3M, 이는 부채 대 자기자본 비율을 -95% 로 가져옵니다. 총자산과 총부채는 각각 $34.0M 및 $139.6M 입니다.

핵심 정보

-95.02%

부채/자본 비율

US$100.29m

부채

이자보상배율n/a
현금US$17.18m
자본-US$105.54m
총부채US$139.57m
총자산US$34.03m

최근 재무 건전성 업데이트

Recent updates

내러티브 업데이트 • Jun 25

BTAI: At Home Agitation Opportunity Will Drive Future Upside Potential

Analysts have reiterated their $14.00 price target on BioXcel Therapeutics, reflecting only slight adjustments in assumptions around discount rate, profit margin and future P/E, and indicating that their overall valuation view on the stock remains largely unchanged. What’s in the News for BioXcel Therapeutics BioXcel Therapeutics reported new positive exploratory efficacy data from the Phase 3 SERENITY At-Home trial of BXCL501 for agitation in bipolar disorders or schizophrenia in the at-home setting, showing reduced agitation versus placebo across mild, moderate, and severe baseline symptom levels, with benefit maintained over repeated dosing, source: 2026 American Society of Clinical Psychopharmacology Annual Meeting.
내러티브 업데이트 • Jun 05

BTAI: At Home Agitation Franchise Will Unlock Future Upside Potential

Analysts have lifted their price target on BioXcel Therapeutics stock to $17, up from $14, citing what they view as a differentiated at-home agitation franchise, expanding BXCL501 neuropsychiatry options, and a wide gap between the current enterprise value and the company's risk adjusted cash flow potential. What's in the News BioXcel Therapeutics reported new positive data from the Phase 3 SERENITY At-Home trial of BXCL501 in agitation tied to bipolar disorders or schizophrenia in the at home setting, with exploratory analyses showing reduced agitation versus placebo across mild, moderate, and severe baseline symptoms, and benefit observed with repeated dosing.
내러티브 업데이트 • Apr 27

BTAI: At Home Agitation Opportunity Will Drive Future Upside Despite Dilution

Analysts have reset BioXcel Therapeutics' blended price target closer to $6, reflecting recent equity dilution while still pointing to what they view as attractive upside from the company's differentiated at home agitation franchise and expanding BXCL501 neuropsychiatry opportunities. Analyst Commentary Recent Street commentary on BioXcel Therapeutics centers on how to balance dilution driven pressure on the share price with what analysts see as meaningful potential around the BXCL501 franchise and the broader neuropsychiatry pipeline.
내러티브 업데이트 • Apr 12

BTAI: At Home Agitation Franchise Will Drive Future Repricing Despite Dilution

Narrative Update The analyst fair value estimate for BioXcel Therapeutics has been adjusted slightly to $14.00 from $14.25, as analysts weigh the recent equity dilution against ongoing views that BXCL501's at-home agitation use and broader neuropsychiatry potential support a higher upside than current trading levels suggest. Analyst Commentary Recent Street research highlights a split view on BioXcel Therapeutics, with some analysts focused on the long-term potential of BXCL501 and others more focused on balance sheet pressure from equity issuance.
내러티브 업데이트 • Mar 27

BTAI: At Home Agitation Expansion Will Drive Repricing Despite Dilution Concerns

Analysts now set an updated $14.25 price target for BioXcel Therapeutics, refining their outlook as they weigh enthusiasm around the at-home agitation franchise and expanding BXCL501 options against recent and expected equity dilution. Analyst Commentary Recent Street research reflects a split view on BioXcel Therapeutics, with some analysts emphasizing upside tied to the at-home agitation portfolio and others focusing more on the impact of equity dilution on upside potential.
내러티브 업데이트 • Mar 12

BTAI: At Home Agitation sNDA Will Drive Repricing Despite Equity Dilution Concerns

Analysts have trimmed their fair value estimate for BioXcel Therapeutics from $15.25 to $14.25, reflecting a lower price target after recent Street research highlighted equity dilution as a key concern. Analyst Commentary Bullish Takeaways Bullish analysts still see upside potential even after the price target adjustment to US$6, suggesting they believe current valuation already reflects a good portion of the equity dilution risk.
내러티브 업데이트 • Feb 25

BTAI: At Home Agitation sNDA And Planning Will Drive Repricing Potential

Analysts kept their $15.25 price target for BioXcel Therapeutics unchanged, citing relatively steady modeled fair value, a similar discount rate and revenue outlook, and only modest tweaks to profit margin and future P/E assumptions. What's in the News Completed an updated market opportunity assessment for IGALMI for acute agitation in bipolar disorder or schizophrenia in the at home setting, using insights from the SERENITY At Home study to guide launch planning.
내러티브 업데이트 • Feb 10

BTAI: At Home Agitation Use Expansion Will Drive Repricing Potential

Analysts now see fair value for BioXcel Therapeutics at US$15.25, down from US$16.75. This reflects updated assumptions for growth, profitability and a higher future P/E multiple in their models.
내러티브 업데이트 • Jan 27

BTAI: At Home Agitation Approval Effort Will Drive Repricing Potential

Analysts have revised their price target for BioXcel Therapeutics to US$16.75, with the change largely tied to updated assumptions for the discount rate, profit margin outlook, and a slightly lower future P/E multiple. What's in the News Submitted a supplemental New Drug Application (sNDA) to the U.S. FDA for IGALMI for at home treatment of agitation tied to bipolar disorders or schizophrenia, aiming to expand use beyond healthcare provider supervised settings where there are currently no FDA approved options (Key Developments).
내러티브 업데이트 • Jan 10

BTAI: At Home Agitation sNDA And Safety Data Will Drive Repricing

Analysts have modestly reset their price target for BioXcel Therapeutics to US$16.75. This reflects updated assumptions around discount rate, profit margin, and future P/E that keep their fair value view broadly unchanged.
내러티브 업데이트 • Dec 17

BTAI: At Home Agitation Approval Pathway Will Drive Bullish Repricing

Narrative Update on BioXcel Therapeutics Analysts have modestly lifted their price target on BioXcel Therapeutics, citing a reaffirmed fair value estimate near $16.75 per share, supported by stable long term growth and profitability assumptions, despite a slightly higher discount rate and modestly richer projected valuation multiples. What's in the News Shareholders are scheduled to vote at the December 12, 2025 AGM on an amendment to the certificate of incorporation that would enable a reverse stock split, which may reflect efforts to maintain listing compliance and improve share price optics (company filing).
내러티브 업데이트 • Dec 03

BTAI: Phase 3 At Home Agitation Data Will Drive Bullish Repricing

Analysts have raised their price target on BioXcel Therapeutics to $4 from $2, citing stronger long term risk adjusted sales potential for BXCL501 supported by positive Phase 3 SERENITY At Home data, while still flagging financing uncertainty. Analyst Commentary Analysts updating their models following the SERENITY At Home readout are highlighting both improved long term revenue potential and persistent execution risks that temper the valuation upside.
내러티브 업데이트 • Nov 19

BTAI: Strong Phase 3 Study Results Will Drive Further Market Momentum

Analysts have lowered their fair value estimate for BioXcel Therapeutics from $23.75 to $16.75 per share, citing improved long-term revenue projections and profit margins. This outlook is balanced by ongoing uncertainties related to the company’s financing strategy.
내러티브 업데이트 • Nov 04

BTAI: Upcoming Regulatory Milestones Will Drive Momentum Following Key Phase 3 Success

Analysts have increased their fair value price target for BioXcel Therapeutics from $19 to $23.75, citing improved revenue growth expectations, a higher profit margin forecast, and optimism following positive BXCL501 study results as well as expanded indications. Analyst Commentary Recent analyst updates reflect a mix of optimism and ongoing caution surrounding BioXcel Therapeutics following positive developments for BXCL501 and improving financial projections.
User avatar
새로운 내러티브 • Apr 17

BXCL501 And SERENITY Trials Will Unlock New Treatment Horizons

Advancing Phase III trials and successful SERENITY outcomes could expand market access and boost revenue through FDA approvals and new partnerships.
분석 기사 • Jun 04

Shareholders May Be More Conservative With BioXcel Therapeutics, Inc.'s (NASDAQ:BTAI) CEO Compensation For Now

Key Insights BioXcel Therapeutics will host its Annual General Meeting on 10th of June CEO Vimal Mehta's total...

재무 상태 분석

단기부채: BTAI 에는 음의 주주 지분이 있는데, 이는 단기 부채를 감당하지 못하는 단기 자산보다 더 심각한 상황입니다.

장기 부채: BTAI는 마이너스 주주 지분을 갖고 있어 장기 부채를 충당하지 못하는 단기 자산보다 더 심각한 상황입니다.

부채/자본 비율 추이 및 분석

부채 수준: BTAI 은 부정주주자본을 갖고 있는데, 이는 높은 부채 수준보다 더 심각한 상황입니다.

부채 감소: BTAI는 주주 지분이 음수이므로 부채가 시간이 지남에 따라 감소했는지 확인할 필요가 없습니다.

대차대조표

현금 보유 기간 분석

과거에 평균적으로 손실을 기록해 온 기업의 경우, 최소 1년 이상의 현금 보유 기간이 있는지 평가합니다.

안정적인 현금 활주로: BTAI 현재 무료 현금 흐름을 기준으로 1년 미만의 cash runway를 보유하고 있습니다.

예측 현금 활주로: 무료 현금 흐름이 매년 2.5 %의 역사적 비율로 계속 감소할 경우 BTAI 의 현금 활주로는 1년 미만입니다.

건전한 기업 찾아보기

7D

1Y

7D

1Y

7D

1Y

기업 분석 및 재무 데이터 상태

데이터최종 업데이트 (UTC 시간)
기업 분석2026/08/05 09:20
종가2026/08/05 00:00
수익2026/03/31
연간 수익2025/12/31

데이터 소스

당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.

패키지데이터기간미국 소스 예시 *
기업 재무제표10년
  • 손익계산서
  • 현금흐름표
  • 대차대조표
분석가 컨센서스 추정치+3년
  • 재무 예측
  • 분석가 목표주가
시장 가격30년
  • 주가
  • 배당, 분할 및 기타 조치
지분 구조10년
  • 주요 주주
  • 내부자 거래
경영진10년
  • 리더십 팀
  • 이사회
주요 개발10년
  • 회사 공시

* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.

별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.

분석 모델 및 스노우플레이크

이 보고서를 생성하는 데 사용된 분석 모델의 세부 정보는 당사의 GitHub 페이지에서 확인하실 수 있습니다. 또한 보고서 사용 방법에 대한 가이드와 YouTube 튜토리얼도 제공하고 있습니다.

Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.

산업 및 섹터 지표

산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.

분석가 소스

BioXcel Therapeutics, Inc.는 9명의 분석가가 다루고 있습니다. 이 중 3명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.

분석가기관
Anita DushyanthBerenberg
Guyn KimBMO Capital Markets Equity Research
Alec StranahanBofA Global Research